Optimizing Trelegy Prior Authorization for Dermatology Practices

Navigating High-Volume Drug PAs: The Trelegy Context

While Trelegy is primarily prescribed for respiratory conditions, its status as a high-volume prior authorization target across commercial, Medicare Advantage, and Medicaid managed care plans underscores the universal challenge of managing complex drug approvals. Dermatology practices, like all specialties, must contend with a broad spectrum of PA requirements for medications that may fall outside their core therapeutic area, demanding robust, adaptable PA workflows.

Dermatology's Specific Prior Authorization Burden

Beyond general drug PAs, dermatology prior authorization is heavily concentrated in biologics for chronic conditions like psoriasis, psoriatic arthritis, atopic dermatitis, and hidradenitis suppurativa. Additionally, specialty topicals and high-cost procedures such as Mohs micrographic surgery for non-melanoma skin cancers frequently trigger PA requirements, demanding specialized documentation and clinical pathway adherence.

Key PA-Triggering Categories in Dermatology

• Biologics for psoriasis, psoriatic arthritis, atopic dermatitis, and hidradenitis suppurativa
• Mohs micrographic surgery for non-melanoma skin cancers in cosmetically sensitive areas
• Advanced skin cancer treatments, including immunotherapy and targeted therapies
• Phototherapy, particularly when prescribed for self-administered home use
• Specific biopsy and excision codes that may require prior approval based on payer policy

Essential Documentation for Dermatology Prior Authorizations

• Diagnosis criteria and disease severity scores (e.g., PASI, BSA, EASI, SCORAD)
• Documentation of prior topical therapy trials and conventional systemic therapy (e.g., methotrexate, cyclosporine)
• Evidence of TB and hepatitis screening pre-biologic initiation
• Site and tumor type specifics for Mohs surgery, conforming to AAD Appropriate Use Criteria (AUC)
• Age-appropriate criteria for pediatric indications and adherence to NCCN guidelines for advanced skin cancers

Common Denial Vectors in Dermatology Prior Authorization

Dermatology PAs frequently encounter denials due to issues such as non-compliance with step therapy protocols for biologics, insufficient documentation of disease severity, or a mismatch with Mohs AUC. Biosimilar substitution requirements for TNF inhibitors and gaps in pre-biologic screening (e.g., TB, hepatitis) are also prevalent reasons for delays and denials, impacting patient access to critical treatments.

Klivira's Strategic Approach to Dermatology PA Automation

Klivira's platform addresses the unique complexities of dermatology prior authorization through intelligent automation. We incorporate AAD-guideline-aware step-therapy logic for biologics, validate Mohs surgery requests against AUC, and manage periodic re-authorization workflows for chronic conditions. Our system also supports medical-vs-pharmacy benefit routing, streamlining submissions across diverse payer requirements and reducing administrative burden.